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Abstract. Drug transporters are recognized as key players in the processes of drug absorption,
distribution, metabolism, and elimination. The localization of uptake and efﬂux transporters in organs
responsible for drug biotransformation and excretion gives transporter proteins a unique gatekeeper
function in controlling drug access to metabolizing enzymes and excretory pathways. This review seeks to
discuss the inﬂuence intestinal and hepatic drug transporters have on pharmacokinetic parameters,
including bioavailability, exposure, clearance, volume of distribution, and half-life, for orally dosed drugs.
This review also describes in detail the Biopharmaceutics Drug Disposition Classiﬁcation System
(BDDCS) and explains how many of the effects drug transporters exert on oral drug pharmacokinetic
parameters can be predicted by this classiﬁcation scheme.
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INTRODUCTION
Since the discovery of Pgp in 1976 (1), the importance of
drug transporters in inﬂuencing the pharmacokinetics of
orally dosed drugs has become increasingly evident (2–4).
Drug transporters in both the gut and the liver can help
control access of drugs to systemic circulation by dictating the
amount of drug that enters the body from the gut lumen and
inﬂuencing how much drug escapes ﬁrst pass metabolism in
both gut and liver. The Biopharmaceutics Drug Distribution
and Classiﬁcation System (BDDCS) can be a helpful tool in
predicting the effects that drug transporters in the gut and
liver will have on a drug’s pharmacokinetic proﬁle (5). The
BDDCS is a modiﬁcation of the Biopharmaceutics Classiﬁca-
tion System (BCS) proposed by Amidon et al.( 6) that is based
on the permeability and solubility characteristics of a drug
compound. This review seeks to brieﬂy discuss intestinal and
hepatictransporters,reviewtheBDDCS,summarizetheeffects
oftransporters inboth the gut andtheliver onpharmacokinetic
parameters of orally dosed drugs, and seek how to potentially
predict some of these effects using the BDDCS.
TRANSPORTERS
A large amount of work has identiﬁed and characterized
intestinal and hepatic transporters in regards to tissue
expression proﬁles, regulation, mechanisms of transport,
substrate and inhibitor proﬁles, species differences, and
genetic polymorphisms. A detailed review of this work is
beyond the scope of this article, but further information can
be found in several recent extensive reviews (7–20).
Both uptake and efﬂux transporters are important in
determining oral drug disposition by controlling absorption
and bioavailability. See Figs. 1 and 2 for their localization in
enterocytes and hepatocytes and Table I for examples of
substrates for those transporters expressed in the intestine
and/or liver. The major uptake transporters responsible for
xenobiotic transport belong to the two solute carrier (SLC
and SLCO) superfamilies. The SLC superfamily members
typically transport Type I organic anions (21), cations, and
zwitterions (22), while the SLCO superfamily transports Type
II organic anions (21). Members of the SLC and SLCO
families use a variety of porter mechanisms (i.e. uniporter,
antiporter, symporter), not all of which have been fully
elucidated for each speciﬁc transporter. In general, these
transporters do not utilize an energy source other than a
chemiosmotic gradient created by translocation of ions across
the membrane (7,9,23–25). The SLC superfamily encom-
passes a variety of transporters, including the organic anion
transporters (OAT, SLC22A), the organic cation transporters
(OCT, SLC22A), the electroneutral organic cation trans-
porters (OCTN, SLC22A), the equilibrative nucleoside trans-
porters (ENT, SLC29), the concentrative nucleoside
transporters (CNT, SLC28), the apical Na
+−dependent bile
salt transporter (ASBT, SLC10), the monocarboxylate
transporters (MCT, SLC16), and the peptide transporters
(PEPT, SLC15). The SLCO family is made up of the organic
anion transporting polypeptides (OATP).
Efﬂux transporters expressed in the intestine and liver
include P-glycoprotein (Pgp, ABCB1), bile salt export pump
(BSEP, ABCB11), multidrug resistance proteins (MRP1- 6,
ABCC1-6), and breast cancer resistance protein (BCRP,
ABCG2), all members of the ATP-Binding Cassette super-
family (14,26). Members of this superfamily use ATP as an
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These transporters’ expression in the intestine and/or
liver, the two major sites affecting how much drug will get
into the body after an oral dose, makes factors affecting their
function important determinants of oral drug pharmacokinet-
ics. Regulatory elements controlling their protein levels,
genetic polymorphisms leading to increased or reduced
function, and coadministration with inhibitors are all impor-
tant avenues by which a transporter’s ability to transport
substrates is altered. While an extensive discussion of these
factors is not the purpose of this review, Tables I, II, and III
list commonly used transporter inhibitors, established poly-
morphisms shown to have an effect in human clinical studies,
and known regulatory elements for some transporters.
THE BIOPHARMACEUTICS DRUG DISPOSITION
CLASSIFICATION SYSTEM (BDDCS)
The BDDCS (5) is a modiﬁcation of the BCS (6), in
which compounds are categorized in four classes according to
their permeability and solubility, characteristics that will
greatly inﬂuence oral absorption. The BCS (See Fig. 3) was
developed to aid in predicting in vivo pharmacokinetic
behavior from in vitro solubility and in vitro or in vivo
permeability measurements. The FDA, hoping to ease
regulatory and ﬁnancial burdens, enacted the BCS as a
methodfordeterminingwhichcompoundsmayreceiveawaiver
for in vivo bioavailability and bioequivalence testing (27).
Class 1 compounds, having high solubility and perme-
ability, formulated as immediate release solid dosage forms
that display rapid dissolution may be eligible for the waiver.
Solubility is relatively easily determined; however this is not
the case with permeability. The FDA, in implementing the
BCS, considers a highly permeable compound as one that
achieves 90% absorption in humans (27). This is based on the
ﬁnding that all of the compounds initially studied in human in
situ gut permeability studies (28,29) exhibiting permeability
equal to orgreater thanmetoprolol (1.34×10
−4 cm/sec;17 of 29
compounds) show equal or more than 90% extent of
absorption in humans. In contrast, those 12 compounds
exhibiting permeability less than metoprolol were less than
90% absorbed in humans. This is an unfortunate coincidence
with the potential for confusing applicability, since permeability
is a rate parameter, whereas percent absorption is an
extent parameter, and they are not interchangeable. A
situation can be envisioned in which a compound has low
permeability but achieves high absorption. For example,
sotalolexhibitsalowPappintheapicaltobasolateraldirectionof
1.53±0.29 (×10
−6 cm/sec) in a Caco2 cell line yet has 95%
absorption compared to other compounds with similar Papp
values that show only 50% (atenolol) and 70% (acebutolol)
absorption (30).
The recognition that BCS Class 1 and 2 compounds are
mainly eliminated by metabolism while Class 3 and 4
compounds are mainly eliminated by biliary or renal excre-
tion of unchanged drug led to the development of the
BDDCS (See Fig. 4 and Table IV) by Wu and Benet (5), in
which the permeability characteristic was replaced by route of
elimination. It is believed that extent of metabolism (by
oxidative Phase 1 and conjugative Phase 2 enzymes) is an
appropriate surrogate for permeability since for a drug to get
metabolized, it must get absorbed (31). Generally, a drug’s
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Fig. 1. Enterocyte with intestinal uptake (green) and efﬂux (blue)
transporters. Multidrug resistance protein (MDR), Multidrug resis-
tance associated protein (MRP), Breast cancer resistance protein
(BCRP), Monocarboxylate transporter protein (MCT), Peptide
transport protein (PEPT), Organic anion transporting polypeptide
(OATP), Organic cation transporter (OCT), apical sodium-depen-
dent bile acid transporter (ASBT), Concentrative nucleotide trans-
porter (CNT), Electroneutral organic cation transporter (OCTN),
Equilibrative nucleoside transporter (ENT). Adapted from Custodio
et al.( 58).
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Fig. 2. Hepatocyte with hepatic uptake (green) and efﬂux (blue)
transporters. Multidrug resistance associated protein (MRP), Organic
cation transporter (OCT), Organic anion transporter (OAT), Organic
anion transporting polypeptide (OATP), sodium-taurocholate
cotransporting polypeptide (NTCP), P-glycoprotein (Pgp), Multidrug
resistance protein (MDR), Breast cancer resistance protein (BCRP),
Bile salt export pump (BSEP). Adapted from Custodio et al.( 58).
2040 Shugarts and BenetTable I. Substrates and Inhibitors of Intestinal and Hepatic Transporters
Substrates Inhibitors
Gut/Apical Gene (Protein)
SLC16A1 (MCT1) lactate, pyruvate, benzoic acid (96) AR-C117977 (111)
SLC15A1 (PEPT1) ampicillin, captopril, valacyclovir (97) 4-aminomethylbenzoic acid, Lys[Z(NO(2))]-Pro (112,113)
SLC15A2 (PEPT2) ampicillin, captopril, valacyclovir (97) cefadroxil, captopril (114)
SLCO2B1 (OATP2B1) estrone-3-sulfate, atorvastatin (98) rifampin, bromosulfophthalein (97)
SLCO1A2 (OATP1A2) estrone-3-sulfate, deltorphin II, fexofenadine (99) rifampin, bromosulfophthalein (97)
SLC22A3 (OCT3) cimetidine (97) corticosterone, decynium22 (115)
SLC10A2 (ASBT) bile salts (taurocholate) (100) S-8921, SC-435 (116,117)
SLC28A1 (CNT1) thymidine, zidovudine, zalcitabine (101) adenosine (118)
SLC28A2 (CNT2) guanosine, ribavirin (102) thymidine (119)
SLC22A4 (OCTN1) quinidine, verapamil (97) cimetidine, pyrilimine, verapamil (120)
SLC22A5 (OCTN2) quinidine, verapamil (97) pyrilamine, TEA (121)
ABCB1 (Pgp) digoxin, fexofenadine, indinavir, vincristine, colchicine, GG918, verapamil (97)
topotecan, paclitaxel (97)
ABCC2 (MRP2) indinavir, cisplatin, glutathione-, glucuronide-,
sulfate-conjugates (97,103)
MK-571, cyclosporine (97,122)
ABCG2 (BCRP) rosuvastatin, doxorubicin, sulfasalazine, topotecan,
daunorubicin (97)
FTC, Ko-143 (123)
ABCC4 (MRP4) topotecan, ceftizoxime, cefazolin, urate (104,105) MK-571 (122)
Gut/Basolateral Gene (Protein)
SLCO3A1 (OATP3A1) PGE1, PGE2, BQ-123, vasopressin (106)
SLCO4A1 (OATP4A1) deesteriﬁed unoprostone carboxylate (107)
SLC22A1 (OCT1) acyclovir, amantadine, desipramine, ganciclovir,
metformin (97)
montelukast (124)
SLC22A2 (OCT2) amantadine, cimetidine, memantine (97) bromosulfophthalein (125)
ABCC1 (MRP1) adefovir, indinavir (97) MK-571, probenecid (122,126)
ABCC3 (MRP3) etoposide, methotrexate, tenoposide (97) MK-571, indomethacin (122,127)
ABCC4 (MRP4) topotecan, ceftizoxime, cefazolin (105,106) MK-571 (122)
ABCC5 (MRP5) cGMP, methotrexate, mercaptopurine (108) MK-571, sildenaﬁl( 122,128)
SLC16A1 (MCT1) lactate, pyruvate, benzoic acid (96) AR-C117977 (111)
SLC29A1 (ENT1) adenosine (109) nitrobenzylmercaptopurine riboside, dipyridamole
(130,131)
SLC29A2 (ENT2) ddC (2'3'-dideoxycytidine), AZT
(3'-azido-3'-deoxythymidine),
nitrobenzylmercaptopurine riboside, dipyridamole
(130,131)
ddI (2',3'-dideoxyinosine) (110)
Hepatic/Apical Gene (Protein)
ABCB1 (Pgp) digoxin, fexofenadine, indinavir, vincristine, colchicine, GG918, verapamil (97)
topotecan, paclitaxel (97)
ABCB4 (MDR3) digoxin, paclitaxel, vinblastine (97) cyclosporine, vinblastine, verapamil (132)
ABCC2 (MRP2) indinavir, cisplatin, ciproﬂoxacin, glutathione-,
glucuronide-,
MK-571, probenecid (122,126)
sulfate-conjugates (97,103)
ABCB11 (BSEP) vinblastine (97) cyclosporine, troglitazone (133)
ABCG2 (BCRP) rosuvastatin, doxorubicin, sulfasalazine, topotecan,
daunorubicin (97)
FTC, Ko-143 (123)
Hepatic/Basolateral Gene (Protein)
SLC22A1 (OCT1) acyclovir, amantadine, desipramine, ganciclovir,
metformin (97)
prazosin, verapamil (134)
SLCO1B1 (OATP1B1) rifampin, rosuvastatin, methotrexate, pravastatin,
thyroxine (97)
rifampin (86,97)
SLCO1B3 (OATP1B3) digoxin, rifampin, methotrexate (97) rifampin (86,97)
SLCO2B1 (OATP2B1) estrone-3-sulfate, atorvastatin (98) rifampin (86)
SLCO1A2 (OATP1A2) estrone-3-sulfate, deltorphin II, fexofenadine (99) rifampin (86)
SLC10A1 (NTCP) rosuvastatin (97) bosentan, propranolol, cyclosporine (135,136)
SLC22A7 (OAT2) zidovudine (97) pravastatin, probenecid, taurocholate (137,138)
ABCC3 (MRP3) etoposide, methotrexate, tenoposide (97) MK-571, indomethacin (122,127)
ABCC4 (MRP4) topotecan, ceftizoxime, cefazolin (104,105) MK-571 (122)
ABCC5 (MRP5) cGMP, methotrexate, mercaptopurine (108) MK-571, sildenaﬁl( 122,128)
ABCC6 (MRP6) cisplatin, daunorubicin (97) verapamil, indomethacin, benzbromarone (122,129)
2041 Transporter Role in Oral Drug Pharmacokineticselimination route is much easier to determine than its extent
of absorption or its permeability in humans. Currently, there
are several methods for determining drug permeability
detailed in the FDA CDER guidance (27). Human pharma-
cokinetic studies to determine mass balance or absolute
bioavailability can be used, but they can be affected by high
inter-subject variability and are expensive and time-consum-
ing. Human in vivo intestinal perfusion studies, extensively
reviewed by Lennernas et al.( 32), are useful, and several
methods are available to conduct these experiments, but they
have the same drawbacks as pharmacokinetic studies. Intes-
tinal perfusion studies with representative animal models
either in vivo or in situ, or excised tissue studies with human
or animal intestinal tissue are other options, as are in vitro cell
studies in an epithelial cell line, such as Caco2 monolayers
(27). While the use of animal models is less expensive and
time-consuming than human studies, there are species differ-
ences in expression and substrate proﬁles for transporters and
metabolic enzymes that can lead to misclassiﬁcation of
compounds (33–35). Indeed, the CDER guidance recom-
mends that non-human systems be used only for compounds
transported by passive processes (27). When using human cell
lines in permeability studies, care must be taken to ensure
that expression levels of transporters are representative of
those seen in vivo (36–38); otherwise, discrepancies could
arise between in vitro and in vivo results.
The use of human liver microsomes, microsomes gener-
ated from Sf9 insect cells expressing recombinant metabolic
enzymes, and isolated human and animal hepatocytes are
widely used to help determine if a drug will be eliminated by
metabolism. Simple incubation experiments will determine if
a compound is a substrate for metabolizing enzymes and can
be followed by in vivo animal and human studies to
determine the importance of metabolism as a route of
elimination. Information on elimination route is obtained by
measuring parent drug and metabolite levels in plasma and
urine collected during Phase 1 human pharmacokinetic
studies.
In the BDDCS framework, if a drug is ≥90% metabo-
lized (a conservative estimate that matches the 90% absorbed
Table III. Examples of Clinically Relevant Polymorphisms
Gene (Protein) SNP Haplotype Clinical Association
ABCB1 (Pgp) 3435C>T reduced digoxin exposure (150)
3435C>T increased digoxin exposure (151)
2677G>T increased digoxin exposure (152)
C3435C>T, 2677G>A decreased fexofenadine exposure (153)
ABCC2 (MRP2) -1549G>A, -1019A>G, -24C>T, 1249G>A, reduced irinotecan-associated diarrhea (154)
IVS26, -34T>C, and 3972C>T
ABCG2 (BCRP) 421C>A reduced diﬂomotecan bioavailability (155)
421C>A increased topotecan bioavailability (156)
421C>A decreased rosuvastatin exposure (157)
SLCO1B1 (OATP1B1) 388A>G, 521T>C increased pravastatin exposure (158)
521T>C increased pravastatin exposure (159)
521T>C increased fexofenadine exposure (160)
521T>C increased repaglinide exposure (161)
388A>G 388A>G, 521T>C increased pitavastatin exposure (162)
521T>C increased rosuvastatin exposure (163)
521T>C increased atorvastatin exposure (163)
521T>C increased nateglinide exposure (164)
521T>C increased atrasentan exposure (165)
388A>G 388A>G, 521T>C increased irinotecan exposure (166)
388A>G, 521T>C increased ezetimibe exposure (167)
521T>C increased torsemide exposure (168)
SLCO1B3 (OATP1B3) T334G, G699A increased mycophenolic acid exposure (169)
SLC22A1 (OCT1) R61C, G401S, 420del G465R, 420del; G174S, 420del increased metformin exposure (65)
Table II. Regulatory Nuclear Hormone Receptors and Ligands
Gene (Protein) Nuclear Receptor Ligand
ABCB1 (MDR1) PXR, CAR rifampin (139,140)
ABCC2 (MRP2) PXR, CAR, FXR rifampin, phenobarbital, chenodeoxycholic acid (141)
ABCC3 (MRP3) PXR, CAR rifampin, phenobarbital (142)
ABCC4 (MRP4) CAR rifampin (143)
ABCG2 (BCRP) PPARg rosiglitizone (144)
ABCB11(BSEP) FXR chenodeoxycholic acid (145)
SLC10A1 (NTCP) GR dexamethasone(146)
SLCO1A2 (OATP1A2) PXR rifampin (147)
SLCO1B1 (OATP1B1) PXR rifampin (142,148)
SLCO1B3 (OATP1B3) FXR chenodeoxycholic acid (149)
2042 Shugarts and Benetcriteria currently used in BCS), then based on solubility, the
drug can be designated as Class 1 or 2. The ≥90% absorption
of BCS (21) and the recommendation of Benet et al.( 23)t o
add ≥90% metabolized as an alternative basis for allowing a
waiver of in vivo bioequivalence are regulatory issues. Wu
and Benet (5) recommend for transporter predictions utiliz-
ing ≥70% metabolism for Class 1 and 2 drugs and <70%
metabolism for Class 3 and 4 drugs. They point out that in
fact very few marketed drugs fall into the 30 to 70%
metabolism category and that most drugs are either exten-
sively metabolized (≥70%) or markedly poorly metabolized
(<30%).
The main difﬁculty in utilizing BCS to make predictions
about drug disposition, and particularly the effect of trans-
porters, relates to the fact that the FDA has promulgated a
regulatory deﬁnition of permeability that differs from the
scientiﬁcd e ﬁnition. The FDA deﬁnes a drug as BCS Class 1
when the extent of absorption (a thermodynamic measure) is
≥90%, and then states that this is a highly permeable (a
kinetic measure) compound even when measured permeabil-
ity is low. This ambiguity is reﬂected in the recent paper of
Chen and Yu (39). Our laboratory is in the process of
addressing this issue in more detail (40). Talinolol is an
excellent example of the BCS/BDDCS difference. Talinolol is
listed in all BCS compilations as a Class 2 drug because it has
a high extent of absorption. However, its measured perme-
ability is low (41). BDDCS classiﬁes talinolol as a Class 4
drug because it is not metabolized, and thus predicts its poor
permeability and it being a substrate for both an uptake and
efﬂux transporter as demonstrated by Shirasaka et al.( 41).
One of the major misconceptions of the scientiﬁc
community is that BCS and BDDCS allow prediction of the
extent of absorption. Because FDA has confounded perme-
ability and extent of absorption, BCS cannot predict absorp-
tion. That is, a drug is considered to be highly absorbed in
BCS as a result of the absorption measurement, independent
of whether permeability is high or low. In contrast, if a drug is
extensively metabolized via Phase 1 and Phase 2 enzymes,
BDDCS predicts it will be highly absorbed. However, if a
drug is poorly metabolized, BDDCS provides no predictions
of the extent of absorption; it may be high (in some cases
because of transporters) or low. BDDCS, however, tells you
that transporters must be evaluated.
The BDDCS allows for some general predictions regard-
ing the role of transporters in oral drug disposition based
upon the drug’s classiﬁcation (Fig. 5). The relevant trans-
porters in terms of BDDCS class in Fig. 5 reﬂect what Wu
and Benet observed for the great majority of drugs in each
class. Of course, such a simple categorization in only four
classes for all drugs cannot be expected to be universally true
with no exceptions, as stated by Wu and Benet (5). It is even
more difﬁcult to hypothesize universal scientiﬁc explanations
for these ﬁndings. However, those proposed by Wu and
Benet (5) as possible explanations are as follows: Class 1
drugs are highly permeable and highly soluble, allowing them
to pass through the gut lumen unaided by transporters. This
will occur even if a Class 1 compound is a substrate in vitro
for an uptake or efﬂux transporter expressed in the gut. This
is hypothesized to occur because the gut is sufﬁciently leaky,
so that the high permeability of these drugs does not give the
transporter sufﬁcient access to the drug or, alternatively, the
drug’s physicochemical properties allow it to achieve a high
enough concentration in the lumen and within enterocytes
that it will saturate any such transporter and be independent
of transporter effects (5). Class 2 drugs are also highly
permeable, so they will generally be able to enter enterocytes
by passive diffusion, unaided by uptake transporters. How-
ever, due to low solubility limiting lumenal concentration,
they are unlikely to saturate efﬂux transporters. Consequent-
ly, Class 2 compounds can be efﬂuxed out of enterocytes and
subject to efﬂux transporter effects that can inﬂuence
bioavailability and absorption rate.
Of the two explanations above for high permeability,
only the ﬁrst, i.e., that the hepatocyte is sufﬁciently leaky, so
that the high permeability of these drugs does not give the
transporter sufﬁcient access to the drug, seems reasonable for
Class 1 drugs. At this time, we have no good explanation for
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Fig. 3. The Biopharmaceutics Classiﬁcation System (BCS) as put
forth by Amidon et al.( 6) and deﬁned by the FDA (21).
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Fig. 4. Biopharmaceutics Drug Disposition Classiﬁcation System
(BDDCS) as put forth by Wu and Benet (5).
2043 Transporter Role in Oral Drug Pharmacokineticswhy certain (but not all) Class 2 drugs are substrates for
hepatic uptake and efﬂux transporters. Perhaps the explana-
tion of Fagerholm (42) that difference in the degrees of
“high” permeability dictate whether the compound will be a
substrate for transporters is correct, but this requires further
investigation. Class 3 compounds have high solubility but low
permeability, while Class 4 compounds have both low
solubility and low permeability. For both of these classes,
drug is unable to get into enterocytes unless aided by an
uptake transporter. Even for highly soluble Class 3 drugs, the
need for uptake transport will limit the intra-enterocyte drug
concentration, making saturation of efﬂux transporters un-
Table IV. Classiﬁcation of 172 Drugs by BDDCS adapted from Wu and Benet (5)
Class 1: High Solubility/Extensive Metabolism Class 2: Low Solubility/Extensive Metabolism
Abacavir Ketoprofen Albendazole Ketoconazole
Acebutolol Ketorolac Amiodarone Lansoprazole
Acetaminophen Labetolol Atorvastatin Lopinavir
Albuterol Levamisole Azathioprine Lovastatin
Allopurinol Levodopa Azithromycin Mebendazole
Amitryptiline Lidocaine Carbamazepine Meﬂoquin
Antipyrine Meperidine Carvediol Nalidixic acid
Buspirone Metoprolol Chlorpromazine Naproxen
Caffeine Metronidazole Cisapride Nelﬁnavir
Chloramphenicol Midazolam Clofazamine Nevirapine
Chlorpheniramine Minocycline Cyclosporine Nifedipine
Codeine Misoprostol Danazol Oxaprozin
Colchicine Morphine Dapsone Phenytoin
Cyclophosphamide Phenobarbital Diclofenac Piroxicam
Desipramine Phenylalanine Diﬂunisol Praziquantel
Dexamethasone Prednisolone Efavirenz Raloxifene
Diazepam Primaquine Felodipine Rifampin
Diltiazem Promazine Flurbiprofen Ritonavir
Diphenhydramine Promethazine Glipizide Saquinavir
Disopyramide Propranolol Glyburide Sirolimus
Doxepin Pyrazinamide Griseofulvin Spironolactone
Enalapril Quinidine Haloperidol Sulfamethoxazole
Ergonovine Quinine Ibuprofen Tacrolimus
Ergotamine Rosiglitizone Indinavir Tamoxifen
Ethinyl estradiol Salicyclic acid Indomethacin Terfenadine
Fluoxetine Sotolol Itraconazole Warfarin
Glucose Theophylline Ivermectin
Hydralazine Valproic acid
Imipramine Verapamil
Isoniazid Zidovudine
Isosorbid dinitrate
Class 3: High Solubility/Poor Metabolism Class 4: Low Solubility/Poor Metabolism
Acyclovir Ganciclovir Acetazolamide
Amiloride Hydrochlorothiazide Aluminum hydroxide
Amoxicillin Lamivudine Amphotericin
Atenolol Levoﬂoxacin Chlorothiazide
Atropine Lisinopril Chlorthalidone
Bidisomide Lithium Ciproﬂoxacin
Bisphosphonates Lomeﬂoxacin Colistin
Captopril Metformin Digoxin
Cefazolin Methotrexate Furosemide
Cetirizine Metoclopramide Neomycin
Chloroquine Nadolol Nystatin
Cimetidine Neostigmine Oﬂoxacin
Cloxacillin Penicillins Phenazopyridine
Dicloxacillin Pitavastatin Talinolol
Doxycycline Pravastatin
Ephedrine Pyridostigmine
Erythromycin Ranitidine
Ethambutol Riboﬂavin
Famotidine Tetracycline
Fexofenadine Trimethoprim
Fluconazole Valsartan
Folinic acid Zalcitabine
2044 Shugarts and Benetlikely. Therefore, both Class 3 and Class 4 drugs may be
subject to uptake and efﬂux transporter effects.
ORAL BIOAVAILABILITY (F) AND EXPOSURE
(AREA UNDER THE CONCENTRATION-TIME
CURVE)
Oral bioavailability is deﬁned as the fraction of a dose
administered that is absorbed into systemic circulation intact
(43). It is a function of the fraction of the dose that is
absorbed in the enterocytes (FA), the fraction of the absorbed
dose that passes through the gut membranes intact (FG), and
the fraction passing through the liver intact (FH) before
reaching the systemic blood supply (Eq. 1). Transporters will
help modulate F of drugs by playing a role in how much drug
gets across the gut membranes and how much drug is taken
up into hepatocytes.
F ¼FA   FG   FH ð1Þ
Bioavailability is proportional to the area under the
concentration-time curve (AUC), which is a measure of drug
exposure (Eq. 2). Consequently, transporter effects on F will
result in a corresponding effect on AUC. Changes in AUC
are easier to determine than those on F, since both in vivo
oral and IV studies are needed to quantitate absolute
bioavailability. Many drugs are only available in either oral
or IV formulations, but not both.
F ¼ CL   AUC ðÞ =DOSE ð2Þ
The concept of bioavailability relates to Eq. 2. For an IV
dose, bioavailability is assumed to be complete, i.e. F=1.
Thus, assuming clearance (CL) to be constant between the IV
and oral dosings, oral F may be determined by comparing
exposure for oral and IV doses, while correcting for any
differences in dose between the two studies. In situ and ex situ
experiments with individual organs, such as the intestine or
liver, using perfusion techniques are very useful for studying
transporter effects on F, and coupling results from these
organ experiments with whole animal and human AUC data
can help elucidate the mechanisms involved in altering both
bioavailability and drug exposure.
In the gut, Class 1 and 2 compounds have favorable
permeability characteristics, allowing them to enter enter-
ocytes unaided by apical uptake transporters. As explained
above, due to their high solubility and rapid permeability,
Class 1 compounds also readily bypass efﬂux transporters or,
alternatively, the high concentrations likely saturate apical
efﬂux transporters, and, therefore, Class 1 drug AUC and F
will not be inﬂuenced by efﬂux transporters even if they are
substrates in vitro. Cao et al.( 44) demonstrated this in situ
with an intestinal rat perfusion model in which they deter-
mined verapamil and propranolol permeabilities and showed
that they were independent of Pgp expression level, which
increased 6-fold along the intestinal tract from the duodenum
to the ileum. While the status of propranolol as a Pgp
substrate is unclear, it is well recognized that verapamil is a
good Pgp substrate. Although AUC and F of Class 1
compounds are independent of apical efﬂux transporters,
such efﬂux transporters will inﬂuence AUC and F of Class 2
compounds. Due to their low solubility, the low concentration
of Class 2 compounds should not saturate apical efﬂux
transporters as Class 1 compounds can. Therefore, apical
efﬂux transporters will be able to pump drug back out into
the lumen where it may re-enter enterocytes, thus allowing
repeated exposure to drug metabolizing enzymes within the
enterocytes. This interplay between apical gut efﬂux trans-
porters and metabolizing enzymes within enterocytes has
been well-characterized using in vitro and in vivo systems
(45,46). Cummins et al. used both a Caco2 cell line over-
expressing CYP3A4 (45) and a rat intestinal perfusion model
(46) to demonstrate the importance of Pgp in inﬂuencing
metabolism of K77, a cysteine protease inhibitor and dual
substrate of Pgp and CYP3A4. In brief, both the cell line
studies and the intestinal perfusion studies showed that Pgp
inhibition increased intracellular K77 concentrations or
appearance in mesenteric blood while decreasing polarized
transport. No corresponding changes were seen for the
CYP3A4 substrates felodipine (45), a Class 2 compound that
is not a substrate of Pgp, or midazolam (46), a Class 1
compound not inﬂuenced by Pgp in the gut. The effects of
inducing Pgp have been shown to yield opposite effects to
that for Pgp inhibition in vivo with the Class 2 (BCS)/Class 4
(BDDCS) compound talinolol. Schwarz et al.( 47) induced gut
Pgp by pretreatment with St. John’s Wort and saw a
signiﬁcant reduction (25%) in F compared to the water
control. Likewise, Westphal et al.( 48) saw a signiﬁcant
(~20%) reduction in F for talinolol when Pgp was induced
with rifampin. While the interplay between Pgp and CYP3A4
has been extensively studied, this phenomenon may also
occur with other enterocytic drug metabolizing enzymes
(CYP3A4, CYP2C9, CYP2C19, CYP2C8, CYP2D6,
esterases, epoxide hydrolases, UGT1A1, UGT1A7–10,
SULT1E1, SULT2A1, SULT1A3, N-acetyltransferases,
glutathione-S-transferases) (49), and other apical efﬂux trans-
porters (i.e., BCRP, MRP2). One such example is provided by
Sesink et al.( 50). Using Mrp2 knockout mice and the speciﬁc
Bcrp1 inhibitor FTC, they showed in an in situ intestinal
perfusion model that inhibiting apical efﬂux of quercetin
glucuronides by Bcrp1 increased plasma quercetin levels
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Fig. 5. Transporter effects predicted by BDDCS following oral
dosing.
2045 Transporter Role in Oral Drug Pharmacokineticsmore than 2-fold after enzymatic hydrolysis of the plasma
samples. Another example is provided by Su et al.( 51)i n
which rat ileal perfusions were performed with topotecan in
the presence and absence of novobiocin, a Bcrp1 inhibitor.
With novobiocin, a∼50% decrease in intestinal secretion was
seen with a corresponding increase in permeability, indicating
that Bcrp1 inhibition inﬂuences topotecan absorption and
bioavailability. Currently it is difﬁcult to study BCRP and
MRP2 interactions in human clinical studies due to the lack of
speciﬁc inhibitors that can be used in people. Also, many
drugs are substrates for multiple efﬂux transporters. Pgp and
BCRP have extensive substrate overlap, and, therefore, one
transporter may compensate when the other is inhibited. In
preclinical studies, the use of knockout animals can circum-
vent this problem, but an effective strategy for human studies
remains to be found. More studies with these other gut
enzymes and efﬂux transporters are needed to fully charac-
terize the importance of their potential interplay in inﬂuenc-
ing AUC and F of substrate drugs.
BDDCS Class 3 and 4 drugs, which have low permeabil-
ity, require apical uptake transporters to help them cross the
luminal barrier, since their low permeability limits diffusion
into enterocytes. Clinical studies have shown that inhibition
of apical gut uptake transporters can also inﬂuence plasma
levels of substrate drugs. Glaeser et al.( 52) showed that
administration of grapefruit juice concomitantly or 2 h prior
to dosing the Class 3 compound fexofenadine, an OATP1A2
substrate, decreased fexofenadine plasma levels compared to
water control, as well as dosing of grapefruit juice 4 h prior to
fexofenadine dosing. Since fexofenadine, like all BDDCS
Class 3 drugs, is not extensively metabolized, the authors
concluded that the effect was due to inhibition of OATP1A2
uptake of fexofenadine. Kato et al.( 53) demonstrated in
mouse pharmacokinetic and Ussing chamber studies that
celiprolol absorption was signiﬁcantly decreased by bromo-
sulfophthalein (BSP), a broad organic anion transport
inhibitor. They used mdr1a/1b knockout mice to avoid any
confounding effects of Pgp and demonstrated decreased
plasma levels of celiprolol upon BSP coadministration in the
pharmacokinetic studies. They conﬁrmed that the effect was
due to decreased absorption in Ussing chamber studies by
showing that BSP signiﬁcantly reduced A to B permeability.
Induction of intestinal uptake transporters conversely should
increase the AUC and F of their substrates. A rat pharma-
cokinetic study by Koitabashi et al.( 54) demonstrated that
administration of orange juice signiﬁcantly increased the
AUC of orally dosed pravastatin while having no effect on
IV pravastatin, indicating a change in F. They further
investigated mRNA and protein levels of rat Oatp1a1 and
Oatp1a4 and saw signiﬁcant increases in both for each
transporter. In addition to the rat studies, Koitabashi et al.
(54) also ran a human study to examine the effect of orange
juice on oral pravastatin. As with the rats, a signiﬁcant
increase in AUC was seen, although a corresponding IV
study was not possible to provide evidence that the change
was due to increased F.
Class 3 and 4 drugs also have the potential to be
inﬂuenced by efﬂux transporters, since they are unlikely to
attain intracellular concentrations high enough to saturate
efﬂux transporters. Dahan et al.( 55) examined the effect of
intestinal Pgp on two Class 3 compounds, famotidine and
cimetidine. They determined in rat in situ intestinal perfusion
studies that differential Pgp expression in the proximal
jejunum versus the distal ileum led to different famotidine
and cimetidine permeabilities in these segments with signif-
icantly decreased permeability seen in the distal segment
compared to the proximal segment, corresponding to the
higher Pgp expression observed in the distal segment. Upon
Pgp inhibition by verapamil, a signiﬁcant increase in perme-
ability for both compounds was seen in the distal ileum
segment, while no signiﬁcant difference was seen in the
proximal jejunum. The distal ileum permeability approached
the permeability seen in the proximal jejunum segment,
effectively making permeability constant along the small
intestine in the presence of verapamil. Evidence supporting
the effect of apical gut efﬂux on BDDCS Class 4 drug
absorption also exists for digoxin, a Pgp substrate. A human
clinical study by Greiner et al.( 56) showed that induction of
Pgp by rifampin decreased the absorption of orally dosed
digoxin, even though digoxin is not metabolized by CYPs in
humans. Subjects received either IV or oral digoxin before
and after Pgp induction. Pgp induction was examined by
immunohistochemistry and Western blot analysis of duode-
num samples and was shown to increase 3.5-fold after
~2 weeks of rifampin dosing. F was signiﬁcantly decreased
(19%) after Pgp induction. Further work is required to fully
characterize the effect of gut apical transporters on Class 3
and 4 drugs.
The inﬂuence of intestinal basolateral uptake and efﬂux
transporters has not yet been examined in depth to determine
their inﬂuence on AUC and F; however, we can predict what
effects they may have based on what we predict for the effects
of apical transporters. Table V summarizes the effects of
intestinal drug transporters on AUC by BDDCS class.
The BDDCS is also useful for making predictions
regarding food effects on orally dosed drugs. The AUC and
F of many compounds are greatly affected by concomitant
food intake, and the FDA recommends that high fat meals
(800–1000 cal: 50–65% from fat, 25–30% from carbohydrates,
15–20% from protein) be used in food-effect studies in the
guidance “Food Effect Bioavailability and Fed Bioequiva-
lence Studies” (57). Many factors are believed to contribute
to these food effects, including changes in gastric emptying
time, bile ﬂow, pH of the intestine, splanchnic blood ﬂow, and
gut wall metabolism. A variety of evidence exists supporting
food effects on transporters as well and is described in detail
in a review by Custodio et al.( 58). The BDDCS is able to
Table V. Predicted Effect of Intestinal Drug Transporters on
Exposure (AUC) by BDDCS Class
BDDCS Class  1 2 3 4
Inhibition
Apical Uptake 
Apical Efflux       
Basolateral Uptake  ?    
Basolateral Efflux  ?
Induction
Apical Uptake     
Apical Efflux 
Basolateral Uptake  ?
Basolateral Efflux  ?    
2046 Shugarts and Benetpredict what is seen clinically in food effect studies. These
predictions are explained if it holds that high-fat meal
components inhibit apical gut uptake and efﬂux transporters.
Fig. 6 summarizes the effects of high fat meals on F and tmax
by BDDCS Class (5,58).
Drug that makes it across the intestinal barrier passes
into the hepatic portal vein and travels to the liver, the ﬁnal
major site for ﬁrst-pass effects, before reaching the systemic
circulation. Drug transporters will play a role in determining
how much drug enters hepatocytes and is exposed to hepatic
drug metabolizing enzymes and biliary excretion. In hepato-
cytes, basolateral uptake transporters function to take drug
up from the sinusoidal blood into hepatocytes while baso-
lateral efﬂux transporters pump drug back out into the
sinusoidal blood. Apical transporters face the bile ducts;
therefore, apical efﬂux transporters will pump drug into the
bile.
The major predictive difference for the BDDCS system
between the gut and the liver relates to the importance of
uptake transporters for BDDCS Class 2 drugs. It is possible
that the intestinal membrane may be “leakier” than the
hepatic membrane, allowing more drug to diffuse across the
intestinal barrier than the hepatic barrier. For example, while
BDDCS Class 2 compounds do not require uptake trans-
porters to get into enterocytes, it has been shown that hepatic
uptake transporters can be an important determinant of drug
entry into hepatocytes and could thereby affect F through the
ﬁrst pass effect and AUC through the combination of the ﬁrst
pass effect and subsequent passages through the liver. Tirona
et al.( 59) demonstrated that the Class 2 compound rifampin
could be transported by OATP1B1 and, to a lesser extent,
OATP1B3 expressed in HeLa cells. Su et al.( 60) determined
that OATP1A2 is able to transport saquinavir, also a Class 2
compound, in oocytes and in HepG2 cells, a human
hepatocellular liver carcinoma cell line. The AUC and F of
Class 3 and 4 drugs, due to their low permeability, will also be
inﬂuenced by hepatic uptake transporters. Watanabe et al.
(61) investigated the importance of hepatic uptake trans-
porters on the plasma levels of the Class 3 compound
pravastatin. They developed a physiologic based pharmaco-
kinetic (PBPK) model that incorporated hepatic sinusoidal
uptake and demonstrated the sensitivity of plasma levels to a
change in uptake. Decreasing uptake transporter activity to 1/
3 of control led to simulated pravastatin plasma levels 271%
of the control, while increasing uptake transporter activity to
3x the control led to simulated plasma levels 14% of control.
Hepatic basolateral efﬂux transporters (i.e., MRP3, 4, 5, 6)
may inﬂuence AUC and F since they provide an avenue of
exit from hepatocytes. As in the intestine, it is possible that
these membrane-bound transporters can interact with drug
before it interacts with metabolizing enzymes associated with
the endoplasmic reticulum. Altering these transporters’
function could affect the AUC and F of their substrates by
altering ﬁrst pass hepatic metabolism or biliary excretion.
Theoretically, the apical efﬂux transporters could also affect
AUC and F by helping to control intra-hepatocyte drug
levels, although this effect would be dependent on the drug’s
ability to get back out of the hepatocyte into sinusoidal blood
either by diffusion or by basolateral efﬂux. A summary of the
effects of hepatic drug transporters on AUC is given in
Table VI and explicated in the next section.
CLEARANCE (CL)
Clearance is technically deﬁned as a proportionality
factor that relates the rate of elimination of drug to the
systemic drug concentration (43). It must be kept in mind that
metabolism that occurs in the gut and ﬁrst pass in the liver
does not contribute to CL, since that drug is lost before it
reaches systemic circulation. For orally dosed drugs, CL and
F are intimately associated and cannot be separated unless
corresponding IV studies have been done. Since this review
deals with orally dosed drugs, we will discuss transporter
effects on CL/F in addition to the intrinsic clearance by the
liver.
CL ¼ F   DOSE=AUC ð2aÞ
CL=F ¼DOSE=AUC ð2bÞ
Gut transporters will exclusively affect F, thus CL will
not change in response to induction or inhibition of gut
transporters, only F will. For orally dosed drugs the liver and
 
Class 1 
 
 
Fextent 
 
tmax 
Class 3 
 
 
Fextent 
 
tmax 
Class 4
 
 
Fextent 
 
tmax 
Class 2 
 
 
Fextent 
 
tmax 
E
x
t
e
n
s
i
v
e
 
M
e
t
a
b
o
l
i
s
m
 
P
o
o
r
 
 
M
e
t
a
b
o
l
i
s
m
 
High Solubility Low Solubility 
Fig. 6. Predicted high fat meal effects by BDDCS classiﬁcation after
Wu and Benet (5).
Table VI. Predicted Hepatic Effect of Drug Transporters on
Exposure (AUC) by BDDCS Class
BDDCS Class  1 2 3 4
Inhibition 
Apical Efflux    
Basolateral Uptake    
Basolateral Efflux 
Induction 
Apical Efflux 
Basolateral Uptake 
Basolateral Efflux    
2047 Transporter Role in Oral Drug Pharmacokineticsthe kidneys are the major eliminating organs, and their
clearances are additive.
TotalCL ¼ CLH þ CLR ð3Þ
CLH can further be divided into uptake and elimination
processes, with the latter divided into biliary excretory
clearance and hepatic metabolic clearance (43). Both mech-
anisms can be affected by transporters.
Transporters in the liver and kidney can affect the CL of
the portion of an orally administered drug that escapes the
ﬁrst-pass effect. Hepatic uptake transporters are expressed on
the basolateral surface of hepatocytes facing the sinusoidal
blood supply. Inhibiting these transporters prevents drug
from being exposed to metabolizing enzymes within hepato-
cytes, decreasing the CLH of drugs that are substrates for
these enzymes. For drugs that are not metabolized but are
eliminated by biliary excretion, CLH may also decrease, since
drug is prevented from getting into the bile through the
hepatocytes. Conversely, induction of hepatic uptake trans-
porters will increase the amount of drug able to get into
hepatocytes and thus gain exposure to metabolizing enzymes
or get pumped into the bile, thereby increasing CLH. CL/F
will change in the same direction as CLH for each case, but
the CL value is not separable from F based on oral data
alone. In addition to basolateral uptake transporters, hep-
atocytes also express basolateral efﬂux transporters that
pump drug back out into the sinusoidal blood. The effects
of inhibiting or inducing these transporters will be opposite
those for the basolateral uptake transporters. Inhibiting
basolateral efﬂux will cause more drug to remain inside
hepatocytes and will lead to increased CLH either by
increased exposure to metabolizing enzymes or to efﬂux into
the bile, while inducing them will lead to more drug being
pumped out of hepatocytes and decreased CLH. Again, CL/F
will change in the same direction as CLH.
Class 1 compounds, due to their high permeability,
appear not to be inﬂuenced by basolateral hepatic uptake
transporters. In the gut, Class 2 compounds are not strongly
inﬂuenced by apical uptake transporters due to their high
permeability; however, it has been shown that at least some of
these compounds are inﬂuenced by basolateral hepatic
uptake transporters. A human pharmacokinetic study by
Lau et al.( 62) showed that an IV dose of the OATP inhibitor
rifampin signiﬁcantly decreased CL/F of atorvastatin, pre-
sumably by decreasing basolateral uptake by OATP1B1
leading to decreased hepatic metabolism by CYP3A4. In
vitro studies showed that 50 μM rifampin did not inhibit
CYP3A4 metabolism of atorvastatin, and rifampin plasma
levels in the human study were ∼15 μM, indicating that
inhibition of hepatic metabolism was not a causal factor in
reducing CL/F. Similar results were seen by Zheng et al.( 63)
in a human study examining the effect of IV rifampin on
orally dosed glyburide, an OATP2B1 substrate. Upon multi-
ple dosing of rifampin, but when rifampin was no longer
present in the systemic circulation, glyburide CL/F was
signiﬁcantly increased compared to the control, due to
induction of metabolic enzymes and transporters. As stated
earlier, we have no good explanation for why some BDDCS
class 2 compounds are substrates for hepatic uptake trans-
porters but this is not seen for BDDCS class 1 compounds. It
is difﬁcult to imagine a scientiﬁc explanation based on a
solubility effect in the liver. This is an area requiring further
investigation.
As expected due to their low permeability potential, the
CL/F of Class 3 and 4 drugs also can be inﬂuenced by
basolateral hepatic uptake transporter effects. Studies with
the Class 3 drugs pravastatin and pitavastatin have shown the
effects of decreased function of OATP1B1 on CL/F. Deng
et al.( 64) performed human clinical studies looking at the
effect of genotype of OATP1B1 (OATP1B1*1a homozygotes
versus OATP1B1*15 homozygotes) on pitavastatin and
pravastatin pharmacokinetics. They saw that CL/F for both
compounds was signiﬁcantly decreased in subjects with
OATP1B1*15/*15 genotype compared to wildtype (2.07-fold
and 2.88-fold for pravastatin and pitavastatin, respectively).
Metformin, another Class 3 compound and a substrate for
OCT1, has also shown transporter inﬂuence on pharmacoki-
netic parameters. Shu et al.( 65) performed a clinical study to
determine the effect of OCT1 genetic variation on metformin
pharmacokinetics. Metformin was orally dosed in two subject
groups, one group with wildtype OCT1 and the other
composed of subjects carrying at least one reduced function
allele. They found that the CL/F was signiﬁcantly reduced in
the variant allele group.
Hepatic apical efﬂux transporters responsible for pump-
ing drug into the bile may also affect both hepatic metabolic
clearance and biliary excretory clearance of their substrate
drugs. Inhibiting apical efﬂux causes drug to remain trapped
within hepatocytes. If the compound is a substrate for
metabolizing enzymes (BDDCS Class 1 and 2 compounds),
its metabolism will increase due to increased exposure to
enzymes, and CLH will increase. If the drug is not subject to
metabolic transformation but rather is eliminated by biliary
excretion (Class 3 and 4 compounds), its CLH may decrease
due to decreased excretion into bile. An alternative route of
elimination is possible though, which may cause a situation to
arise in which there is no net change in CL/F, but rather a
change in the clearance proﬁle seen as decreased biliary
excretion and increased renal excretion if the drug is
sufﬁciently hydrophilic to be eliminated in the urine. Induc-
tion of hepatic apical efﬂux transport could lead to increased
biliary excretion but decreased metabolic transformation,
making the effect on CLH dependent upon a drug’s substrate
status for metabolizing enzymes. Work remains to be done to
elucidate the effect of hepatic apical efﬂux transporters on
CL/F separate from that of apical gut efﬂux transporters.
While work has been done on determining effects of
hepatic basolateral efﬂux in in situ isolated perfused rat liver
studies (66) and in vivo with intraperitoneal dosing (67), the
effect of hepatic basolateral efﬂux transporters on oral drug
pharmacokinetics has not been extensively studied. However,
we can hypothesize what effects inhibition or induction will
have. Inhibition of hepatic basolateral efﬂux will cause drug
to be trapped within hepatocytes, similar to hepatic apical
efﬂux inhibition, and will lead to increased exposure to drug
metabolizing enzymes or to apical efﬂux. This may lead to an
increase in hepatic metabolic or biliary excretory clearance.
Induction of hepatic basolateral efﬂux will cause more drug
to be pumped back into the sinusoidal blood, decreasing the
hepatic contribution to CL/F, but depending on the drug’s
hydrophilicity may be compensated for by increased renal
CL.
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The elmination half-life is dependent upon CL and
V (Eq. 4).
t1=2   0:693   V=CL ð4Þ
Whatever effects transporters exert on V and CL will
inﬂuence the t1/2, either causing it to increase if the increase
in V predominates, decrease if the increase in CL is more
pronounced, or have no net effect if changes in V and CL
cancel out each other. However, transporters in the gut may
affect the absorption half-life, t1/2,abs (Eq. 5).
t1=2;abs ¼ :693=ka ð5Þ
The rate constant of absorption, ka, may be inﬂuenced
by gut transporters, and the BDDCS can be useful in
predicting which drugs are likely to be affected. As stated
before, Class 3 and 4 drugs are dependent on gut uptake
transporters to get across the luminal membrane. If their
uptake is inhibited, this is likely to decrease their absorption
rate, driving down ka and increasing t1/2,abs. The opposite will
hold true when uptake transporters are induced. The ka will
increase and t1/2,abs will decrease as more drug is pumped into
enterocytes. Parker et al.( 68) ran a human study in which a
single oral dose of digoxin was administered after 5 days
pretreatment with grapefruit juice and saw a signiﬁcant
decrease in the digoxin ka compared to the water control
arm (3.0±2.4 to 1.2±1.0 hr
−1, p<0.05). The plasma
concentration vs. time proﬁle also showed a later tmax.N o
other pharmacokinetic parameters were signiﬁcantly different
between the treatment groups. The ka and tmax results were
not what would be expected if the interaction were due to
Pgp inhibition (68,69), but rather what would be expected
from inhibition of an intestinal uptake transporter. Although
the speciﬁc OATP isoform responsible for intestinal uptake of
digoxin has not been identiﬁed, the drug is known to be an
OATP1B3 (70) substrate. The BDDCS predicts the clinical
results seen by Parker et al., since digoxin is a Class 4
compound in humans and uptake transporter effects will be
important for these compounds. Intestinal efﬂux transporters
may also affect ka and t1/2,abs, especially for Class 2
compounds. If apical efﬂux transporters are inhibited, this
will decrease the “cycling” effect that is seen when a drug is
repeatedly pumped out and gains reentry into enterocytes,
allowing the drug to exit basolaterally more quickly. In a
study on the effects of ABCB1 genotype, Solas et al.( 71)
found that subjects dosed with indinavir (Class 2 compound)
carrying one decreased-function allele, C3435CT, had a
signiﬁcantly higher ka (2-fold) compared to controls and
carriers of two mutant alleles (they explain the lack of
signiﬁcant difference in the C3435TT group as possibly due
to lack of statistical power with the small number of subjects).
The t1/2,abs of Class 3 and 4 compounds may also be subject to
apical efﬂux transporter effects. For the Class 3 compound
fexofenadine, a Pgp substrate (72,73), Tannergren et al.( 74)
determined in human intestinal perfusion studies with the
Gut-I-Loc system that coperfusion of fexofenadine with the
Pgp inhibitor verapamil caused a signiﬁcant increase in ka
compared to the control (0.0030±0.0012 min
−1 to 0.0255±
0.0103 min
−1 (P<.001)), which changes t1/2,abs. Decreasing the
absorption rate often changes the appearance of the plasma
concentration vs. time proﬁle, even if no change in the extent
of absorption as measured by area under the curve (AUC) is
seen. The tmax can shift later and Cmax can decrease, causing
the proﬁle to appear ﬂatter. Increasing the absorption rate
constant may cause tmax to shift earlier and Cmax to increase,
sharpening the plasma concentration vs.t i m ep r o ﬁle. Class
1 drugs, for which transporter effects are minimal, should
not show a signiﬁcant change in the absorption rate
constant or t1/2,abs.
Transporter effects on ka may also have implications for
oral multiple dosing regimens. In a recent analysis, Sahin and
Benet (75)d e ﬁned a new half-life parameter, the operational
multiple dosing half-life (t1/2,op), as “the half-life equal to the
dosing interval at steady-state where the maximum concen-
tration at steady-state is twice the maximum concentration
found for the ﬁrst dose and where the fall off to the trough
concentration from the maximum concentration is consistent
with this half-life.” They found that this t1/2,op parameter for
some drugs may be quite sensitive to changes in ka.I n
simulations with diazepam, decreasing the ka from 2.77 h
−1 to
0.347 h
−1 led to a drastic increase in the t1/2,op, increasing it
from about 13 h to 35 h. Diazepam is a Class 1 drug;
therefore, we would not expect to see transporter effects on
ka. However, further study is warranted to determine what
effect varying ka has on the t1/2,op for Class 2, 3, and 4
compounds through transporter interactions.
VOLUME OF DISTRIBUTION (V)
Volume of distribution is deﬁned as the “volume into
which a drug distributes in the body at equilibrium (43)” and
is a “direct measure of the extent of distribution (43).”
Transporters in the gut will not affect V as it relates the
concentration of drug in the systemic circulation to amount of
drug in the body. Like CL, V for orally administered drugs
cannot be separated from F, and V is reported as V/F. Very
few drugs remain within physiologically realistic volumes
(43), such as the plasma (3 L), extracellular water (16 L), or
total body water (42 L). Instead they distribute into organs
and tissues, greatly increasing their apparent V. Transporters
may inﬂuence V by mediating their transport into and out of
a variety of tissues and organs. The most widely studied sites
thus far in relation to transporter inﬂuence on distribution are
the liver and the brain, but the principles determined for
these organs should hold for other organs and tissues
expressing drug transporters. Several drugs whose site of
action is the liver, including some statins, are concentrated in
the liver by hepatic uptake transporters. If their hepatic
uptake is inhibited, more drug remains in the plasma and less
drug gets into the liver, decreasing V/F. For example, Lau et
al.( 62) saw a signiﬁcant reduction in Vss/F in response to a
single IV dose of rifampin inhibiting the hepatic uptake of
atorvastatin. Zheng et al.( 63) showed a similar effect of
rifampin on the Vss/F for glyburide. Induction may increase
the amount of drug getting into the liver, decrease the amount
in plasma, and increase V/F. While the effects of altering
function of hepatic apical efﬂux transporters may inﬂuence V/
F, this effect isn’t always predictable. Decreasing hepatic
basolateral efﬂux may keep drug within hepatocytes, possibly
2049 Transporter Role in Oral Drug Pharmacokineticsdecreasing plasma levels and increasing V/F, while inducing
basolateral efﬂux may lead to decreased V/F by causing there
to be more drug in the plasma.
An extensive review of transporter effects on V has
recently been published (170).
CONCLUSIONS
Awealth of knowledge exists regarding drug transporters,
and increasingly their effects on pharmacokinetics are being
characterized. Work in the ﬁeld is far from complete though,
and there are many areas in which there is a dearth of
information.
While the substrate and inhibition proﬁles of trans-
porters both new and old are being updated continuously
(76–78), new transporters are still being discovered. For
example, Engel et al.( 79) recently cloned the proton-
stimulated organic cation transporter (PMAT) expressed in
the intestine, and Zhou et al.( 80) determined that it may play
a role in intestinal transport of metformin. The search goes on
forappropriateprobesubstrates (81–83)andspeciﬁcinhibitors
(84–86) that will allow testing of single transporters without
confounding effects from substrate overlap (12,87,88).
With widespread use of cell models to test substrate
proﬁles and to determine permeabilities, care needs to be
taken to ensure that reproducible results are obtained and to
be aware of factors that can lead to discrepancies between
different laboratories’ results (36,89,90).
The development of models that incorporate different
transporters is a huge step forward in the ﬁeld; however,
these models need valid in vivo parameter values in order to
accurately predict pharmacokinetics under a variety of
conditions (32,91–95). Human and animal studies need to
continue to generate data to develop complete and robust in
silico models.
The understanding of transporter effects on oral phar-
macokinetics has improved vastly over the last 20 years, yet it
is still a vibrant and important area of research needing
continued effort and advancement.
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